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This study aimed to develop liposomes and solid lipid nanoparticles (SLNs) encapsulated with 
n-propylgallate (PG) as potential platforms for nose-to-brain delivery of anticancer drugs. The 
lipid formulation loaded with PG was not studied previously through this administration route, 
therefore its investigation and optimization is promising. The liposomes, solid lipid 
nanoparticles were developed by direct pouring method and solvent injection method 
respectively following the Quality by Design approach. The risk assessment strategy was used 
to screen and rank the critical quality attributes that can affect the final PG loaded 
nanoparticles. The 3-factor Box Behnken Design and Response surface Quadratic models was 
used to optimize the formulations of liposomes and solid lipid nanoparticles respectively. The 
lipid nano-formulation showed good compatibility according to results of XRPD, FTIR and DSC. 
The PG-SLNs showed encapsulation efficiency of 84±0.5%, particle size of 103±46.04 nm with 
polydispersity index of 0.16±0.001 and zeta potential of -36±4.78 mV. The PG-liposomes 
showed 90 ± 3.6% encapsulation efficiency, 167.9 ± 3.5 nm average hydrodynamic diameter, 
0.129 ± 0.002 PDI and -33.9 ± 4.5 zeta potential. In vitro drug release and permeation studies 
of both formulation in simulated nasal conditions were performed. Both lipid 
nanoformulations resulted in enhanced nasal permeability and sustained release of 
nanoformulation compared to the PG solution. The optimized formulations showed high 
potential to be used to target the brain via intranasal route. 
 
Acknowledgements: This work was supported by the Ministry of Human Capacities, Hungary 
(Grant TKP-2020) and by the National Research, Development and Innovation Office, Hungary 
(GINOP 2.3.2-15-2016-00060) projects. 
 
References  
Sabir, F et al. Drug Discov. Today 25(1): 185-194. (2020) 
 
Supervisor: Prof. Ildikó Csóka 
 
